Wolfe Research Says West Pharmaceutical Services (WST) is Positioned to Benefit from Injectable Drug Growth

With a net profit margin of 16.85%, West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. 

Wolfe Research analyst Mike Polark upgraded West Pharmaceutical Services, Inc. (NYSE:WST) to Outperform from Peer Perform on June 2. He also assigned a $375 price target to the stock. The analyst described the company’s first-quarter performance as “juicy good,” pointing to ongoing GLP1-related growth and a return to meaningful expansion across the rest of the high-value products segment. According to Polark, West remains well-positioned because of its exposure to injectable drugs, a market that continues to grow and is expected to expand for years.

On May 29, Morgan Stanley increased its price recommendation on WST to $325 from $315. It reiterated an Equal Weight rating on the shares. The revision followed investor meetings with members of the company’s management team earlier in the week. After those discussions, the firm said it “sensed strong conviction in both near- and longer-term execution as top-down catalysts play into the company’s strengths,” according to the analyst.

West Pharmaceutical Services, Inc. (NYSE:WST) is a global manufacturer that designs and produces advanced containment and delivery systems for injectable drugs and healthcare products. The company focuses on integrated technologies that support the safe storage and administration of injectable therapies.

READ NEXT: 10 Oversold Dividend Growth Stocks to Buy and Billionaire Ken Fisher’s Top 11 Dividend Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.